Moderna Inc said it had completed the enrollment of 30,000 participants in a late-stage study testing its experimental coronavirus vaccine, with over a third of the participants from communities of color – Reuters reports.
Over 25,650 participants have so far received their second shot of the vaccine candidate, mRNA-1273 – Reuters quotes the company.
The U.S. Food and Drug Administration requires at least two months of safety data after a full vaccination regime to review applications for emergency use authorization of an experimental vaccine.
